Abstract
Prostate cancer is the second most frequent men’s cancer diagnosis and the fifth leading cause of death worldwide. A large percentage of prostate cancers are initially very sensitive to hormone therapies, but over time the sensitivity to antiandrogens may be lost and cancers can develop resistance through various signalling mechanisms. Expression of the androgen receptor splice variant 7 (AR-V7) in some cases is considered as one of the factors supporting antiandrogen resistance. The study aims to develop novel AR-V7 inhibitors for prostate cancer therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
